ROR1 for Lymphoid Cancers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319244.
- Also identified by DOI 10.1056/EVIDe2100014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
ROR1 for Lymphoid Cancers This editorial discusses the first-in-human, phase 1 clinical trial of a novel antibody-drug conjugate, zilovertamab vedotin, in patients with relapsed or refractory mature B-cell malignancies.
Medical subject headings
- Receptor Tyrosine Kinase-like Orphan Receptors